- Home
- CISS vs PCSA Comparison
CISS vs PCSA Comparison
Compare CISS & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- PCSA
- Stock Information
- Founded
- CISS 2022
- PCSA 2011
- Country
- CISS Greece
- PCSA United States
- Employees
- CISS N/A
- PCSA N/A
- Industry
- CISS Marine Transportation
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- PCSA Health Care
- Exchange
- CISS Nasdaq
- PCSA Nasdaq
- Market Cap
- CISS 2.8M
- PCSA 3.3M
- IPO Year
- CISS N/A
- PCSA N/A
- Fundamental
- Price
- CISS $3.30
- PCSA $0.22
- Analyst Decision
- CISS
- PCSA Strong Buy
- Analyst Count
- CISS 0
- PCSA 1
- Target Price
- CISS N/A
- PCSA $6.00
- AVG Volume (30 Days)
- CISS 121.3K
- PCSA 46.5M
- Earning Date
- CISS 08-21-2025
- PCSA 08-12-2025
- Dividend Yield
- CISS N/A
- PCSA N/A
- EPS Growth
- CISS N/A
- PCSA N/A
- EPS
- CISS N/A
- PCSA N/A
- Revenue
- CISS $38,174,754.00
- PCSA N/A
- Revenue This Year
- CISS N/A
- PCSA N/A
- Revenue Next Year
- CISS N/A
- PCSA N/A
- P/E Ratio
- CISS N/A
- PCSA N/A
- Revenue Growth
- CISS N/A
- PCSA N/A
- 52 Week Low
- CISS $2.85
- PCSA $0.15
- 52 Week High
- CISS $23.25
- PCSA $3.10
- Technical
- Relative Strength Index (RSI)
- CISS 41.14
- PCSA 44.28
- Support Level
- CISS $3.20
- PCSA $0.20
- Resistance Level
- CISS $4.00
- PCSA $0.33
- Average True Range (ATR)
- CISS 0.37
- PCSA 0.09
- MACD
- CISS -0.03
- PCSA -0.01
- Stochastic Oscillator
- CISS 8.33
- PCSA 6.53
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).